Techniques to quantify TSH receptor antibodies

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 8, 2008, Pages 461-468

  Ajjan, R A ^a   Weetman, A P ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Autoimmune thyroid disease; Graves disease; Graves ophthalmopathy; TsH receptor antibodies

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; CYCLIC AMP; IMMUNOGLOBULIN; RADIOACTIVE IODINE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY;

ANTIBODY DETECTION; BINDING AFFINITY; BINDING ASSAY; BIOASSAY; CHEMOLUMINESCENCE; CLINICAL FEATURE; CLINICAL TRIAL; ENDOCRINE OPHTHALMOPATHY; GRAVES DISEASE; HORMONE BINDING; HUMAN; HYPERTHYROIDISM; INTERMETHOD COMPARISON; NEWBORN DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RADIOIMMUNOASSAY; RELAPSE; REVIEW;

AUTOANTIBODIES; BIOLOGICAL ASSAY; GRAVES DISEASE; HUMANS; RECEPTORS, THYROTROPIN; THYROIDITIS, AUTOIMMUNE;

EID: 47949112820     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0886     Document Type: Review

References (61)

1. Adams DD (1988) Long-acting thyroid stimulator: how receptor autoimmunity was discovered. Autoimmunity 1: 3-9
2. Rapoport B et al. (1998) The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 19: 673-716
3. Davies TF et al. (2005) Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest 115: 1972-1983
4. Ando T et al. (2005) Thyrotropin receptor antibodies: new insights into their actions and clinical relevance. Best Pract Res Clin Endocrinol Metab 19: 33-52
5. Smith BR and Hall R (1974) Thyroid-stimulating immunoglobulins in Graves' disease. Lancet 2: 427-431
6. Costagliola S et al. (1999) Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 84: 90-97
7. Villalta D et al. (2004) Analytical and diagnostic accuracy of "second generation" assays for thyrotrophin receptor antibodies with radioactive and chemiluminescent tracers. J Clin Pathol 57: 378-382
8. Paunkovic J and Paunkovic N (2006) Does autoantibody-negative Graves' disease exist? A second evaluation of the clinical diagnosis. Horm Metab Res 38: 53-56
9. Preissner CM et al. (2003) Comparison of thyrotropin-receptor antibodies measured by four commercially available methods with a bioassay that uses Fisher rat thyroid cells. Clin Chem 49: 1402-1404
10. Smith BR et al. (2004) A new assay for thyrotropin receptor autoantibodies. Thyroid 14: 830-835
11. Kamijo K et al. (2005) Clinical evaluation of 3rd generation assay for thyrotropin receptor antibodies: the M22-biotin-based ELISA initiated by Smith. Endocr J 52: 525-529
12. Atger M et al. (1999) Autoantibodies interacting with purified native thyrotropin receptor. Eur J Biochem 265: 1022-1031
13. Nagayama Y et al. (1991) Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors. J Clin Invest 88: 336-340
14. Tahara K et al. (1991) Immunoglobulins from Graves' disease patients interact with different sites on TSH receptor/LH-CG receptor chimeras than either TSH or immunoglobulins from idiopathic myxedema patients. Biochem Biophys Res Commun 179: 70-77
15. Costagliola S et al. (2004) Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity. Mol Endocrinol 18: 3020-3034
16. Minich WB et al. (2004) Antibodies to TSH-receptor in thyroid autoimmune disease interact with monoclonal antibodies whose epitopes are broadly distributed on the receptor. Clin Exp Immunol 136: 129-136
17. Morgenthaler NG et al. (2003) Affinity purification and diagnostic use of TSH receptor autoantibodies from human serum. Mol Cell Endocrinol 212: 73-79
18. Morgenthaler NG et al. (2007) Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites. J Clin Endocrinol Metab 92: 1058-1065
19. Zakarija M and McKenzie JM (1973) Effect of thyrotropin and of LATS on mouse thyroid cyclic AMP. Metabolism 22: 1185-1191
20. Stockle G et al. (1981) Micromethod of human thyrocyte cultures for detection of thyroid-stimulating antibodies and thyrotrophin. Acta Endocrinol (Copenh) 97: 369-375
21. Kasagi K et al. (1982) A new in vitro assay for human thyroid stimulator using cultured thyroid cells: effect of sodium chloride on adenosine 3′,5′-monophosphate increase. J Clin Endocrinol Metab 54: 108-114
22. Vitti P et al. (1993) Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor. J Clin Endocrinol Metab 76: 499-503
23. Chiovato L et al. (1994) Detection of antibodies blocking thyrotropin effect using Chinese hamster ovary cells transfected with the cloned human TSH receptor. J Endocrinol Invest 17: 809-816
24. Murakami M et al. (1995) Clinical usefulness of thyroid-stimulating antibody measurement using Chinese hamster ovary cells expressing human thyrotropin receptors. Eur J Endocrinol 133: 80-86
25. Takano T et al. (1997) Detection of thyroid-stimulating antibody using frozen stocks of Chinese hamster ovary cells transfected with cloned human thyrotropin receptor. Endocr J 44: 431-435
26. Watson PF et al. (1998) A new chemiluminescent assay for the rapid detection of thyroid stimulating antibodies in Graves' disease. Clin Endocrinol (Oxf) 49: 577-581
27. Hovens GC et al. (2006) A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease. Clin Endocrinol (Oxf) 64: 429-435
28. Evans C et al. (1999) Development of a luminescent bioassay for thyroid stimulating antibodies. J Clin Endocrinol Metab 84: 374-377
29. Da Costa CR and Johnstone AP (1998) Production of the thyrotrophin receptor extracellular domain as a glycosylphosphatidylinositol-anchored membrane protein and its interaction with thyrotrophin and autoantibodies. J Biol Chem 273: 11874-11880
30. Costagliola S et al. (1998) Production of bioactive amino-terminal domain of the thyrotropin receptor via insertion in the plasma membrane by a glycosylphosphatidylinositol anchor. FEBS Lett 436: 427-433
31. Chazenbalk GD et al. (2002) Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. J Clin Invest 110: 209-217
32. Chazenbalk GD et al. (2004) Thyroid stimulation does not require antibodies with identical epitopes but does involve recognition of a critical conformation at the N terminus of the thyrotropin receptor A-subunit. J Clin Endocrinol Metab 89: 1788-1793
33. Minich WB et al. (2004) A coated tube assay for the detection of blocking thyrotropin receptor autoantibodies. J Clin Endocrinol Metab 89: 352-356
34. Shibayama K et al. (2005) Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease. Endocr J 52: 505-510
35. Inui T et al. (1998) Increase of thyroid stimulating activity in Graves' immunoglobulin-G by high polyethylene glycol concentrations using porcine thyroid cell assay. Thyroid 8: 319-325
36. Schwarz-Lauer L et al. (2002) Evidence for a simplified view of autoantibody interactions with the thyrotropin receptor. Thyroid 12: 115-120
37. Davies TF et al. (1998) Thyroid controversy - stimulating antibodies. J Clin Endocrinol Metab 83: 3777-3785
38. Gilmour J et al. (2000) The quantitative measurement of autoantibodies to thyroglobulin and thyroid peroxidase by automated microparticle based immunoassays in Hashimoto's disease, Graves' disease and a follow-up study on postpartum thyroid disease. Clin Lab 46: 57-61
39. Guilhem I et al. (2006) Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal. Thyroid 16: 1041-1045
40. Lavard L et al. (2000) Prevalence of thyroid peroxidase, thyroglobulin and thyrotropin receptor antibodies in a long-term follow-up of juvenile Graves' disease. Autoimmunity 32: 167-172
41. Feldt-Rasmussen U et al. (1994) Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 78: 98-102
42. Zimmermann-Belsing T et al. (2002) Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. Eur J Endocrinol 146: 173-177
43. Schott M et al. (2004) Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res 36: 92-96
44. Quadbeck B et al. (2005) Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid 15: 1047-1054
45. Cappelli C et al. (2007) Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. Endocr J 54: 713-720
46. Weetman AP (2000) Graves' disease. N Engl J Med 343: 1236-1248
47. Noh JY et al. (2000) Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. Thyroid 10: 809-813
48. Gerding MN et al. (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 52: 267-271
49. Morris JC III et al. (1988) Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods. Mayo Clin Proc 63: 707-717
50. Khoo TK and Bahn RS (2007) Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies. Thyroid 17: 1013-1018
51. Eckstein AK et al. (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91: 3464-3470
52. Khoo DH et al. (2000) Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 10: 1093-1100
53. Fisher DA (1997) Fetal thyroid function: diagnosis and management of fetal thyroid disorders. Clin Obstet Gynecol 40: 16-31
54. Chan GW and Mandel SJ (2007) Therapy insight: management of Graves' disease during pregnancy. Nat Clin Pract Endocrinol Metab 3: 470-478
55. Nayak B and Hodak SP (2007) Hyperthyroidism. Endocrinol Metab Clin North Am 36: 617-56
56. Weetman AP (1994) The immunomodulatory effects of antithyroid drugs. Thyroid 4: 145-146
57. Carella C et al. (2006) Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16: 295-302
58. McGregor AM et al. (1979) Effect of irradiation on thyroid-autoantibody production. Lancet 2: 442-444
59. Bartalena L et al. (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338: 73-78
60. Andrade VA et al. (2004) Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study. Eur J Endocrinol 151: 467-474
61. Mukhtar ED et al. (1975) Relation of thyroid-stimulating immunoglobulins to thyroid function and effects of surgery, radioiodine, and antithyroid drugs. Lancet 1: 713-715